Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol (ORION-13)
Latest Information Update: 26 Mar 2024
At a glance
- Drugs Inclisiran (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Registrational; Therapeutic Use
- Acronyms ORION-13
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 21 Mar 2024 Planned End Date changed from 30 Nov 2024 to 2 Dec 2024.
- 14 Jun 2023 This trial has been Completed in Slovenia, According to European Clinical Trials Database record.
- 19 May 2023 Planned End Date changed from 29 Nov 2024 to 30 Nov 2024.